Navigation Links
Catalyst Biosciences Receives Milestone Payment from Pfizer for Progress in Lead Hemostasis Program
Date:12/16/2010

SOUTH SAN FRANCISCO, Calif., Dec. 16, 2010 /PRNewswire/ -- Catalyst Biosciences, Inc., the leading company in the discovery and development of engineered proteases, today announced the receipt of a $4.0 million milestone payment from Pfizer Inc. under the terms of the collaboration agreement for the development of improved recombinant human Factor VIIa variants for the treatment of hemophilia and other bleeding disorders.  

"We are very encouraged by the progress made to date in our Factor VIIa program, the most advanced program within Catalyst's hemostasis franchise," said Nassim Usman, Ph.D., Catalyst's CEO.  "In addition to our work with Pfizer, Catalyst has independently achieved significant progress in engineering highly differentiated recombinant human Factor IX and Xa variants for acute and prophylactic treatment of bleeding disorders, including both hemophilia and non-hemophilia indications.  Catalyst expects to expand and strengthen this pipeline of novel engineered proteases in the coming year." 

In June 2009 Catalyst and Wyeth LLC (the successor to Wyeth), a wholly owned subsidiary of Pfizer Inc., formed an exclusive, worldwide collaboration for the discovery, development and commercialization of improved, second generation Factor VIIa products.  Total payments under the collaboration, including an upfront payment of $21 million, ongoing research funding, and milestone payments, could exceed $500 million, exclusive of double-digit royalty payments.  

About Catalyst Biosciences  Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases.  Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase
'/>"/>

SOURCE Catalyst Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Catalyst Pharmaceutical Partners to Present at the MoneyShow Conference
2. Catalyst Pharmaceutical Partners Regains Compliance with NASDAQ Minimum Bid Price Rule
3. Catalyst Pharmaceutical Partners to Present at the BioNetwork East 2010 Conference
4. Catalyst Pharmaceutical Partners to Present Today at 2010 Epilepsy Pipeline Update Conference
5. Catalyst Pharmaceutical Partners Selected to Present at Epilepsy Conference Highlighting New and Promising Therapies
6. IDEXX Laboratories Announces Catalyst Dx(R) Placement Total for 2009 and Installed Base of SmartService(TM) Customers
7. Catalyst Pharmaceutical Partners Reports Third Quarter 2009 Financial Results
8. Catalyst Pharmaceutical Partners, Inc. Announces Organizational Changes and Extension of Chief Executives Employment Agreement
9. Catalyst Pharmaceutical Partners, Inc. Announces the Closing of $3.97 Million Registered Direct Offering
10. Sigma-Aldrich(R) Partners With Flow Chemistry Leader ThalesNano to Provide CatCart(R) Catalyst Products for Rapidly Growing Market
11. Catalyst Pharmaceutical Partners, Inc. To Raise $3.97 Million In Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
(Date:7/30/2015)...  ResMed Inc. (NYSE: RMD ) today announced ... for the quarter was $453.1 million, a 9 percent ... (a 17 percent increase on a constant currency basis). ... ended June 30, 2014.  Diluted earnings per share for ... June 30, 2014.  The results for ...
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... MedImmune today announced,that it has initiated a Phase 1/2a ... children one month to 12 months of age to,help ... most common respiratory infection in infants and can cause ... a serious respiratory disease that can have significant effects,on ...
... Partner to Make Direct Investment in CEL-SCI, ... CVM ) announced today that it has expanded ... Co., Ltd. ("Orient,Europharma"), a leading pharmaceutical company from ... also cover South Korea,the Philippines, Australia and New ...
Cached Medicine Technology:MedImmune Advances Pediatric Disease Prevention Program With Start of Phase 1/2a Clinical Trial for Respiratory Syncytial Virus Vaccine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 2CEL-SCI Announces Expansion of Exclusive Licensing Agreement for Cancer Drug Multikine 3
(Date:7/31/2015)... ... 31, 2015 , ... BioViva USA, Inc. (“BioViva”), a to-clinic gene therapy company ... , BioViva announces it has begun a fundraiser through Maximum Life Foundation (“MaxLife”) to ... a cure. MaxLife will grant 100% of the money raised to BioViva to help ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Heart Fit Clinic has increased a patient's ... heart rate of 150 beats versus 100 beats, this is a big deal," says ... give life back to patients with heart disease," he adds. People with angina are ...
(Date:7/31/2015)... York, NY (PRWEB) , ... July 31, 2015 , ... ... kidney disease, according to a study published today in Nature Communications and led by ... conducted in mice, suggests that variations in the gene RTN1 led to greater production ...
(Date:7/31/2015)... ... July 31, 2015 , ... Indosoft, Inc., is pleased ... in Q-Suite 5.9. Q-Suite is their flagship contact center ACD system for Asterisk-based ... script display logic shows the script components to the agent only when wanted, and ...
(Date:7/31/2015)... ... , ... According to WFLA on July 16th, Sarasota has seen ... overdoses. Thricefold deaths have held steady over the last “couple of months” according to ... which was spurred by the crackdown of prescription painkillers. Many users who were addicted ...
Breaking Medicine News(10 mins):Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 2Health News:BioViva USA, Inc.’s Alzheimer’s Disease Gene Therapy Human Trial 3Health News:Heart Fit Clinic Helps Patient Increase Fitness Level with External Counterpulsation 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 2Health News:Mount Sinai Researchers Find Key Gene Drives Kidney Disease Severity 3Health News:Q-Suite 5.9 Adds Validation Tools to Call Center Software Agent Screen 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 2Health News:Sarasota Sufferers Increased Heroin Overdoses and Deaths 3
... reason to deny insurers access to genetic information, argues a ... BMJ. ,Only if we refuse to give ... them seeking genetic test results, says Professor Soren Holm from ... to any health information they would only be able to ...
... of herbal products and medicines has the potential to reach ... the creation of exclusive export promotion zones (EPZ) across ... can be accelerated with the setting up of EPZs in ... rate of over 25 percent in countries like the US, ...
... less than three dollars a year per patient could ... from the trauma and torment of epilepsy, a new ... 85 percent of epilepsy sufferers in the developing world ... the drugs most often prescribed to impede the terrible ...
... find the perfect present this Father's Day? What better way to ... keep him healthy and vital for years to come . This ... check themselves out -- and then get checked out by their ... and over have diabetes. The symptoms of type 2 diabetes, the ...
... getting rid of smoking was more difficult for him than ... ,The former hellraiser, who quit his nicotine addiction in ... hooked to smoking again.,He revealed that before he had kicked ... ,"They're all a b**ger to kick, but I'd ...
... with Prof Vijay K Varadan, an Indian born US ... production of ``glucose watches''. The talks are in the ... ,Varadan holds the post of Director of the Centers ... Density Electronics Center (HiDEC) and Neurosurgery Research Programme in University ...
Cached Medicine News:Health News:Should Genetic Information Be Disclosed to Insurers? 2Health News:Export of Herbal Products to Reach Rs.120 Billion by 2012: Study 2Health News:Small Change Could Stop Epilepsy Seizures for Millions 2Health News:Drag Dad to the Doctor This Father's Day 2Health News:Titan may Produce Glucose Watches Soon 2
Are you looking for an inexpensive, effective Blood and Infusion Warmer? , ,Animec is an economical fluid warmer that uses standard I.V. tubing instead of special disposable sets....
... The reliable, rugged and easy-to-use solution that's ... is required., ,Symeon's light weight and ... moved into any working position. It can ... And excessive cable "spaghetti syndrome" is minimized ...
... Narkomed 6400 Series anesthesia workstation provides ... technologies are combined to provide true ... user. State of the art computer ... onto a single color touchscreen display ...
... Developed to be used in facilities where ... the latest ventilation and gas delivery technologies ... the ability and the functionality of the ... to create yourself a workplace environment that ...
Medicine Products: